Michael Earl
Chief Commercial Officer

Is this your profile?

About

Michael Earl is a veteran of the life sciences industries, with more than 40 years’ experience in both biopharma and medical device companies, as well as in private equity investing. Most recently, he was the Director of the Pharma Services business for Owen Mumford, and immediately before that was the Commercial Vice-President for Bespak. He has extensive experience in the development and commercialisation of drugs, devices and combination products. He currently serves as the Chief Commercial Officer for Eco-Inject alongside consulting for companies and investors in these fields.

Contributions

CONQUERING THE CHALLENGES OF CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT

Michael Earl discusses the factors that need to be taken into account for successful connected drug delivery device development.

More contributions

AREAS TO WATCH IN CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT

Michael Earl identifies areas of development in the field of connected drug delivery devices, providing an insight into what can be expected in the coming years. He draws on Owen Mumford’s own research, as well as discussions with industry experts and counterparts.

#134_2022_Jun_Owen_Mumford_featured

SUPPORTING PATIENTS ON THE ROAD TO SELF-CARE

Michael Earl discusses the importance of transitioning current healthcare models to embrace patient self-management and how advanced drug delivery device technologies, such as connectivity, can ease this burden on overstretched healthcare services.

A CHECKLIST FOR AUTOINJECTOR DESIGN

Michael Earl outlines the five key questions autoinjector designers typically ask during the development process and the choices available for tailoring autoinjector products.

#133_May_2022_OM_Fig2

INTERVIEW: STEVEN KAUFMAN, STEVANATO GROUP, & MICHAEL EARL, OWEN MUMFORD

In this exclusive interview, Steven Kaufman of Stevanato Group, and Michael Earl of Owen Mumford, talked with us about their companies' recent major agreement for the manufacturing and provision of prefillable syringes for the advanced two-step, single-use autoinjector, Aidaptus^®.

SO FAR SO GOOD: MAINTAINING THE MOMENTUM OF PROGRESS FOR SUSTAINABLE POLICIES

Michael Earl discusses the highlights of a review undertaken by Owen Mumford into how the pharmaceutical industry is faring on environmental, social and governance standards, noting that while the industry is performing above average overall, there remain some key areas for improvement.

AIDAPTUS^®: OWEN MUMFORD INTRODUCES ITS NEXT-GENERATION PLATFORM AUTOINJECTOR

Michael Earl introduces the next-generation Aidaptus^® autoinjector, explaining how this latest platform device from Owen Mumford can contribute to a faster speed-to-market, increased flexibility during drug development and improved patient outcomes.

Top